These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 3330253

  • 41. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H, Weidmann P, Fragiacomo C, Noseda G, Bachmann C.
    Schweiz Med Wochenschr; 1985 Jun 29; 115(26):907-11. PubMed ID: 3927481
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M, Brodan V, Kucerová L, Grafnetter D, Kuhn E, Veselková A.
    Cas Lek Cesk; 1980 May 30; 119(22):616-21. PubMed ID: 7427980
    [No Abstract] [Full Text] [Related]

  • 44. A pilot study of the effect of Gemfibrozil on some haematological parameters.
    O'Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC.
    Thromb Res; 1982 May 15; 26(4):275-9. PubMed ID: 6955993
    [Abstract] [Full Text] [Related]

  • 45. CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
    Corder CN, Kloer HU, Price MD.
    Eur J Clin Pharmacol; 1989 May 15; 37(5):477-81. PubMed ID: 2598985
    [Abstract] [Full Text] [Related]

  • 46. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G, Kłosiewicz-Latoszek L.
    Wiad Lek; 1985 Aug 15; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR.
    Artery; 1985 Aug 15; 12(6):363-81. PubMed ID: 4051756
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J, Martorell J.
    Clin Ther; 1980 Aug 15; 3(4):234-41. PubMed ID: 7273061
    [Abstract] [Full Text] [Related]

  • 51. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Aug 15; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 52. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S, La Spina E, Fichera C, Cultrera E, Patanè M, Ciulla P.
    Arch Sci Med (Torino); 1982 Aug 15; 139(4):441-8. PubMed ID: 7168636
    [No Abstract] [Full Text] [Related]

  • 53. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D, Scotti L, Baroni L, Beggi P, Fasoli A.
    Clin Ter; 1980 Mar 31; 92(6):649-55. PubMed ID: 7460493
    [No Abstract] [Full Text] [Related]

  • 54. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E, Michajlik A, Wegrzyn B.
    Pol Tyg Lek; 1983 Sep 26; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract] [Full Text] [Related]

  • 55. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P, Bittolo-Bon G, Alessandrini P.
    Clin Ter; 1981 Jul 15; 98(1):47-61. PubMed ID: 7249572
    [No Abstract] [Full Text] [Related]

  • 56. Clinical experience with bezafibrate.
    Schubotz R, Schneider J, Hausmann L, Mühlfellner G, Mühlfellner O, Kaffarnik H.
    Artery; 1980 Jul 15; 8(6):553-9. PubMed ID: 7259534
    [Abstract] [Full Text] [Related]

  • 57. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K, Mrukowicz M, Kopel E.
    Przegl Lek; 1984 Jul 15; 41(9):581-6. PubMed ID: 6393227
    [No Abstract] [Full Text] [Related]

  • 58. [Preliminary evaluation of the usefulness of determination of apolipoprotein B. cholesterol and VLDL triglyceride concentrations in the early diagnosis of type IV hyperlipoproteinemia].
    Bobilewicz D, Kotlicka J, Grajnert K.
    Pol Tyg Lek; 1981 Mar 02; 36(9):325-6. PubMed ID: 7267451
    [No Abstract] [Full Text] [Related]

  • 59. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M, Nowicka G, Szostak WB, Kłosiewicz-Latoszek L.
    Kardiol Pol; 1982 Mar 02; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract] [Full Text] [Related]

  • 60. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W, Schilling A, Calder D.
    Med Welt; 1980 Apr 04; 31(14):515-20. PubMed ID: 7374415
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.